The US and the UK have followed similar guidance over statins and the National Institute for Health and Care Excellence (NICE), which issues drug guidance recently recommended doubling the eligibility for statins in the over 40s from those with a 20% risk to those with a 10% risk of developing cardiovascular disease.
I do not undersatnd this sentence:
doubling the eligibility for statins in the over 40s from those with a 20% risk to those with a 10% risk of developing cardiovascular disease.
doubling the eligibility ---> does it mean more samples were included or less samples were included?
Does it mean because the eligibility has changed, so the risk of CVD of samples has reduced from 20% to 10%.
really confused me so much..........
Those people who are currently eligible for statin therapy are over 40 years old and have a 20% risk of developing cardiovascular disease (CVD). The guidance is increasing the number of eligible patients by making those who are over 40 years old and have a 10% risk of developing CVD eligible for statin therapy.
Using the word "doubling" is really not appropriate in this case because reducing the eligibility from 20% risk to 10% risk does not necessarily mean you will double the number of eligible patients.
" Doubling the eligibility "---> does it mean the peopulation amount selected would vary? maybe more or less?